Paysign, Inc. (PAYS) SEC Filings & Earnings Calls
EquiReason read 9 Paysign, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Paysign reported strong Q2 2026 results with revenue up 48% YoY, net income up 387% YoY, and operating cash flow turning positive..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 842.4M
- P/E TTM
- 55.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
6 Aug 202610-QPaysign reported strong Q2 2026 results with revenue up 48% YoY, net income up 387% YoY, and operating cash flow turning positive.earningsopen
Figures in the filing · each found in the filing text
| Total revenues · Q2-2026 | $28M | +48% y/y |
| Plasma industry revenue · Plasma · Q2-2026 | $13M | +21% y/y |
| Pharma industry revenue · Pharma · Q2-2026 | $15M | +89% y/y |
| Gross profit · Q2-2026 | $18M | +52% y/y |
| Net income · Q2-2026 | $7M | +387% y/y |
| Basic EPS · Q2-2026 | $0.12 | +300% y/y |
| Cash and restricted cash · 2026-06-30 | $176M | +55% y/y |
| Operating cash flow · H1-2026 | $20M | |
| Gross margin · Q2-2026 | 63.3% |
Risks flagged
Customer concentration
“One pharma patient affordability customer individually represented 36% of our accounts receivable balance.” · word for word
Bank concentration risk
“The Company maintains its cash and cash equivalents and restricted cash in various bank accounts primarily with one financial institution in the United States.” · word for word
5 Aug 20268-K · 2.02Paysign reported record Q2 2026 revenue of $28.3M (+48% YoY), GAAP net income $6.76M, and raised full-year outlook. Pharma revenue surged 89% and plasma revenue grew 21%.earningsopen
Figures in the filing · each found in the filing text
| Total Revenues · Q2-2026 | $28M | +48% y/y |
| Pharma Revenue · Pharma · Q2-2026 | $15M | +89% y/y |
| Plasma Revenue · Plasma · Q2-2026 | $13M | +21% y/y |
| Gross Profit Margin · Q2-2026 | 63.3% | |
| Operating Margin · Q2-2026 | 24.8% | |
| GAAP Net Income · Q2-2026 | $7M | +386% y/y |
| Adjusted EBITDA · Q2-2026 | $10M | +113% y/y |
| Diluted Adjusted EBITDA per share · Q2-2026 | $0.16 | +100% y/y |
| GAAP Diluted EPS · Q2-2026 | $0.11 | +450% y/y |
| Active Pharma Programs · Pharma · 2026-06-30 | 148 |
Guidance
FY26 revenue $114.0M to $117.0M; Adjusted EBITDA $35.0M to $38.0M
Raised full-year outlook citing strong Q2 results and momentum across pharma and plasma businesses.
Risks flagged
Plasma center count declining, though per-center revenue improving
“total net plasma center count decreased by 46 during the past 12 months, exiting the quarter with 561 centers.” · word for word
13 May 202610-QTotal revenues $28M (+51% y/y); Net income $5M (+110% y/y); Gross profit $18M (+56% y/y)open
Figures in the filing · each found in the filing text
| Total revenues · Q1-2026 | $28M | +51% y/y |
| Net income · Q1-2026 | $5M | +110% y/y |
| Gross profit · Q1-2026 | $18M | +56% y/y |
| Operating cash flow · Q1-2026 | $19M |
12 May 20268-K · 2.02Revenue $28M (+51% y/y); Pharma revenue $16M (+82% y/y); Plasma revenue $12M (+25% y/y)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $28M | +51% y/y |
| Pharma revenue · Pharma · Q1-2026 | $16M | +82% y/y |
| Plasma revenue · Plasma · Q1-2026 | $12M | +25% y/y |
| Net income · Q1-2026 | $5M | +110% y/y |
| Adjusted EBITDA · Q1-2026 | $11M | +113% y/y |
| Gross margin · Q1-2026 | 65.0% | |
| Operating margin · Q1-2026 | 23.8% | |
| Unrestricted cash · Q1-2026 | $21M | |
| Active patient affordability programs · Pharma · Q1-2026 | 135 | |
| Net plasma center count · Plasma · Q1-2026 | 573 |
Risks flagged
Plasma center attrition: 20 centers sold to competitors, 2 closed due to underperformance
“We exited the quarter with 573 centers versus 595 centers at the end of 2025 as 20 centers were sold to companies who use a competing provider and two underperforming centers were closed.” · word for word
Stock compensation expense increased 91% to $1.28M, potentially diluting shareholders
“stock compensation expense increased 91.0% to $1.28 million” · word for word
26 Mar 2026DEF 14AAnnual proxy statement filed; no material governance or compensation changes.open
Figures in the filing · each found in the filing text
| Net Income · FY2025 | $8M | +98% y/y |
| Total Shareholder Return (cumulative $100 investment) · FY2025 | $171.00 | +58% y/y |
25 Mar 202610-KTotal revenues $82M (+40% y/y); Gross profit $49M (+51% y/y); Gross margin 59.4; Guidance: No specific numerical guidance provided; management plans to continue investing in growth.open
Figures in the filing · each found in the filing text
| Total revenues · FY2025 | $82M | +41% y/y |
| Gross profit · FY2025 | $49M | +51% y/y |
| Gross margin · FY2025 | 59.4% | |
| Net income · FY2025 | $8M | +98% y/y |
| Adjusted EBITDA · FY2025 | $20M | +107% y/y |
| Adjusted EBITDA margin · FY2025 | 24.3% | |
| Operating cash flow · FY2025 | $52M | +129% y/y |
| Gross dollar volume loaded on cards · FY2025 | $1.94B | +9% y/y |
| Revenue conversion rate · FY2025 | 4.2% | |
| Card programs · FY2025 | 670 |
Guidance
No specific numerical guidance provided; management plans to continue investing in growth.
Management plans to continue investing in technology, sales, marketing, cybersecurity, fraud, customer service, and regulatory compliance in 2026. Believes internally generated funds will support existing business and expansion into new verticals.
Risks flagged
Plasma donation volume decline
“decline in plasma donations and dollars loaded to cards as plasma inventory levels were elevated throughout much of 2025, which has reduced our average monthly revenue per center” · word for word
Regulatory compliance cost
“We operate in a highly regulated environment and are subject to extensive regulation, supervision and examination.” · word for word
Customer concentration
“We have no major customers and are not reliant on any individual card program.” · word for word
24 Mar 20268-K · 2.02Total revenue $82M (+40% y/y); Net income $8M (+98% y/y); Adjusted EBITDA $20M (+107% y/y)earningsopen
Figures in the filing · each found in the filing text
| Total revenue · FY2025 | $82M | +41% y/y |
| Net income · FY2025 | $8M | +98% y/y |
| Adjusted EBITDA · FY2025 | $20M | +107% y/y |
| Pharma revenue · Pharma · FY2025 | $34M | +168% y/y |
| Plasma revenue · Plasma · FY2025 | $46M | +4% y/y |
| Net plasma center count · Plasma · FY2025 | 595 | |
| Active patient affordability programs · Pharma · FY2025 | 131 | |
| Gross margin · FY2025 | 59.4% | |
| Operating margin · FY2025 | 9.0% | |
| Unrestricted cash · FY2025 | $21M |
Risks flagged
Plasma revenue per center declining
“average revenue per plasma center per month of $7,067, down from $7,510” · word for word
Elevated effective tax rate
“effective tax rate of 24.7% versus 7.8%” · word for word
13 Nov 202510-QPaysign reported strong Q3 2025 results with total revenue +41.6% YoY, driven by pharma patient affordability programs (+141.9% YoY), and significant margin expansion.earningsopen
Figures in the filing · each found in the filing text
| Gross Dollar Volume Loaded on Cards · Q3-2025 | $552M | +21% y/y |
| Revenue Conversion Rate · Q3-2025 | 3.9% | |
| Gross Profit Conversion Rate · Q3-2025 | 2.2% | |
| Net Income Conversion Rate · Q3-2025 | 0.4% | |
| Adjusted EBITDA · Q3-2025 | $5M | +78% y/y |
| Adjusted EBITDA Margin · Q3-2025 | 23.3% | |
| Revenue · Q3-2025 | $22M | +42% y/y |
| Gross Margin · Q3-2025 | 56.3% | |
| Net Income · Q3-2025 | $2M | +54% y/y |
| Net Margin · Q3-2025 | 10.3% |
Risks flagged
Plasma Revenue Per Center Decline
“The increase in plasma revenue was primarily due to the addition of 117 net plasma centers during the past 12 months offset by a decline in plasma donations and dollars loaded to cards as plasma inventory levels have normalized, which has reduced our average monthly revenue per center as compared to the same period in the prior year.” · word for word
Operating Cash Flow Volatility
“The changes in accounts receivable, accounts payable, and customer card funding, a net decrease of $12,667,611, are primarily related to the growth in our pharma patient affordability business and timing of pass-through payments as we are invoiced by third-party service providers at the end of the period and are due monies from our pharma patient affordabili” · word for word
12 Nov 20258-K · 2.02Total revenues $22M (+42% y/y); Net income $2M (+54% y/y); Adjusted EBITDA $5M (+78% y/y); Guidance: Expect to add 20-30 pharma programs before year endearningsopen
Figures in the filing · each found in the filing text
| Total revenues · consolidated · Q3-2025 | $22M | +42% y/y |
| Net income · consolidated · Q3-2025 | $2M | +54% y/y |
| Adjusted EBITDA · consolidated · Q3-2025 | $5M | +78% y/y |
| Diluted EPS · consolidated · Q3-2025 | $0.04 | +33% y/y |
| Plasma revenue · plasma · Q3-2025 | $13M | +12% y/y |
| Pharma patient affordability revenue · pharma · Q3-2025 | $8M | +142% y/y |
| Plasma centers · plasma · Q3-2025 | 595 | +25% y/y |
| Active pharma programs · pharma · Q3-2025 | 105 | +59% y/y |
| Average monthly revenue per plasma center · plasma · Q3-2025 | $7122.00 | -11% y/y |
| Average quarterly revenue per pharma program · pharma · Q3-2025 | $75434.00 | +52% y/y |
Guidance
Expect to add 20-30 pharma programs before year end
Record revenue and profitability; pharma segment accelerating; new contact center expansion; positive outlook.
Risks flagged
Decline in average monthly revenue per plasma center due to normalized plasma inventory levels.
“average monthly revenue per plasma center decreased to $7,122 compared to $7,991 for the same period last year” · word for word
Wage inflation and tight labor market increasing customer care costs.
“wage inflation pressures, a tight labor market, and increased benefit costs” · word for word
Plasma center closures: 12 centers closed in Q3 due to underperformance.
“a reduction of 12 centers from the prior quarter, due to planned center closures of underperforming centers” · word for word
Paysign, Inc. — questions
- What did Paysign, Inc. file recently?
- 9 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Paysign reported strong Q2 2026 results with revenue up 48% YoY, net income up 387% YoY, and operating cash flow turning positive.
Every figure on this page comes from Paysign, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.